Compare iShares Core MSCI EAFE ETF (IEFA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Merck & Co., Inc. — how do they compare? iShares Core MSCI EAFE ETF trades at $96.52 (market cap $189.19B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and Merck & Co., Inc. for 98 Days on average.
| IEFA | MRK | |
|---|---|---|
Market Cap | $189.19B | $351.28B |
Volume | 8,441,787 | 7,969,665 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $156.43 |
52-Week Low | $85.06 | $82.49 |
Typical Hold Time | 40 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA (iShares Core MSCI EAFE ETF) trades at $95.87, down 0.34% with bearish technical signals dominating. The ETF manages $196 billion in assets and focuses on developed markets outside North America. Recent comparisons highlight its higher dividend yield versus competitors like Schwab's SCHF and State Street's SPDW, though some alternatives have shown stronger recent performance.
The outlook remains cautious given bearish technical indicators and competitive pressure from lower-cost alternatives. Key risks include international market volatility and currency fluctuations, while the fund's scale and diversification provide stability for long-term international exposure seekers.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
